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Objective: Glucocorticoids (GCs) have been widely used in the management of osteoarthritis (OA) and
rheumatoid arthritis (RA). Nevertheless, there has been some concern about their ability of increasing
reactive oxygen species (ROS) in the cartilage. Forkhead-box class O (FOXO) transcription factors have
been proved to have a protective role in chondrocytes through regulation of autophagy and defending
oxidative stress. The objective of this study was to investigate the role of FOXO3 in Dex-induce up-
regulation of ROS.
Design: Healthy cartilages debris from six patients were used for chondrocytes culture. After the treat-
ment of dexamethasone (Dex), the ROS levels, autophagic ﬂux, the expression of FOXO3 in chondrocytes
were measured. RNA interference technique was also used to determine the role of FOXO3 in Dex-
induced autophagy. The metabolism of the extra-cellular matrix was also investigated.
The results: Dex increased intracellular ROS level, the expression of Akt, FOXO3 as well as autophagy ﬂux
in human chondrocytes. The expression of aggrecanases also increased after the treatment of Dex.
Catalase, the ROS scavenger, suppressed Dex-induced up-regulation of autophagy ﬂux and expression of
aggrecanases and Akt. MK-2206 and LY294002, the PI3K/Akt inhibitors, repressed Dex-induced up-
regulation of FOXO3. Silencing FOXO3 resulted in down-regulation of Dex-induced autophagy. Moreover,
knockdown of FOXO3 increased Dex-induced apoptosis as well as ROS levels in chondrocytes. In addition,
up-regulation of autophagy by Rapamycin resulted in decreasing ROS level in chondrocytes.
Conclusion: Dex could advance the degenerative process in cartilage. Autophagy was induced in response
to Dex-induced up-regulation of ROS via ROS/Akt/FOXO3 signal pathway.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Local administration of glucocorticoids (GCs) has been used in
the management of osteoarthritis (OA), rheumatoid arthritis (RA)
as well sports injuries1,2. GC works via its receptor and inhibits local
immunity reaction3. Therefore, GC plays a critical role in relieving
the symptoms in the patients. However, there has been a growing
body of evidences showed that GCs had a degenerative-effect on
several collagen-producing tissues, such as bone, tendons and
skin4e7. Accordingly, interests have focused on how GCs led to
degeneration in these tissues. However, the mechanism of GC-: X.-D., Chen, Department of




ternational. Published by Elsevier Linduced degeneration is largely unknown. Recently, it has been
reported that the GC could dysregulate the mitochondria function
and therefore induce apoptosis8.
Dysregulation of mitochondria could result in an increase of
intracellular reactive oxygen species (ROS)9. ROS plays a crucial role
in the homeostasis of cell energetic cycling and extra-cellular ma-
trix metabolism. In non-immune cells, endogenous ROS generated
from mitochondria in response to pro-inﬂammatory cytokines and
mechanical stress10. Nevertheless, excessive ROS tightly associated
with degenerative and aging diseases, such as OA, Alzheimer's
disease and Huntington's disease11,12. Recent studies demonstrated
that oxidative stress caused by ROS could induce apoptosis in
chondrocytes8,13,14. Besides, ROS also contributes to the degrada-
tion of cartilage by up-regulation of the expression of matrix
metalloproteinases (MMPs)12,15. Therefore, increasing level of ROS
would advance the pathological process of OA.
Transcription factors of the Forkhead box O class (FOXOs) play
an important role in maintaining the intracellular ROStd. All rights reserved.
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pressions of FOXOs17. FOXOs, in turn, up-regulated the expressions
of anti-oxidant genes, such as SOD2 and sestrin family19. In
contrast, dysregulation of FOXOswould result in an increase in both
cell death rate and intracellular level of ROS in chondrocytes17.
Recently, FOXOs have been reported to be involved in regulation of
autophagy during the pathological processes of aging and OA16.
Autophagy is a critical energy recycling mechanism of eukary-
otic cells20. We and other authors had demonstrated that auto-
phagy could protect the chondrocytes or ﬁbro-chondrocytes
against the ROS and inﬂammatory cytokines21e24. Recently, there
was study showed that autophagy protected chondrocytes from
GC-induced apoptosis25. However, the mechanism of GC-induced
autophagy was largely unknown. In the current study, we investi-
gated the potential signal pathway of GC-induced autophagy. Our
results indicated that dexamethasone (Dex), a synthetic GC,
induced autophagy via ROS/Akt/FOXO3 pathway.
Material and methods
Cells isolation and preparation
After approval by the institutional review board of Xin-Hua
hospital (School of medicine, Shanghai Jiao Tong University),
healthy cartilages debris were obtained from six female patients
(age 20.5 ± 4.7) during the femoroacetabular impingement sur-
geries. To address the potential changes of the phenotypes of the
chondrocytes from these patients, the mRNA expressions of
collagen type I and II in these chondrocytes were investigated.
Health cartilages debris from three female patients (age 15, 24, 27
years) during osteochondral autograft transplantation surgery
were used as control. Before the surgery, every patient was well
informed and an instant consent was assigned. The debris carti-
lages were used for cell culture. The tissue was then minced into
1 mm3 and digested in 0.1% collagenase type II (SigmaeAldrich, St
Louis, MO, USA) for 4e5 h at 37C. Then the debris was seeded in
Dulbecco's Modiﬁed Eagle Medium/Nutrient Mixture F-12 (DMEM/
F-12, Gibco, USA) mediumwith 10% fetal bovine serum (FBS, Gibco,
USA) in a 37C, 5% CO2 environment. After reaching 70% conﬂuence,
the primary passage cells were harvested and replanted. When the
ﬁrst-passage cells reaching 90% conﬂuence, in order to synchronize
the cells, the cultured mediumwas changed to DMEM/F-12 with 1%
FBS and antibiotics for 12 h before further experiments. The real-
time PCR results showed that there was no signiﬁcant difference
in the mRNA expression of collagen type I and II between the
experimental group and control group (Table I).
ROS measurement
The intracellular levels of chondrocytes were measured using a
ROS detection kit (Beyotime, Haimen, China). Cells in 6-well culture
plates were incubatedwith different concentrations of Dex for 24 h.
Harvested cells were washed with serum-free culture medium and
incubated with 10 mM DCFH-DA at 37C for 20 min. Then the dis-
tribution of DCF ﬂuorescence was recorded by a ﬂuorospec-
trophotometer at an excitation wavelength of 488 NM and at anTable I
The phenotypes of FAI chondrocytes
Normal chondrocytes
Collagen type I 2.95 ± 0.52
Collagen type II 2.51 ± 0.36
The gene relative expressions were normalized to GAPDH. Data are reported as scatter
showed that there was no difference in themRNA expression of collagen type I and II bemission wavelength of 535 nm. The ROS level of the chondrocytes
cultured in 10%FBS was used as control.
Western blotting analysis
The protein of treated chondrocytes was separated on SDS-PAGE
and then transferred to a polyvinylidene diﬂuoride membrane as
our previous described22. The membranes were blocked with 5%
BSA followed by immunoblotting with LC3 (1:3000, Abcam, UK),
Beclin-1 (1:300, Abcam, UK), p-Akt (1:500, Abcam, UK), p-P70S6K
(1:500, Abcam, UK), FOXO3 (1:500, Abcam, UK), Bcl-2 (1:1000,
Abcam, UK), Bax (1:1000, Abcam, UK), mTOR (1:2000, Abcam, UK),
ULK1 (1:1000, Abcam, UK), MMP-1 (1:1000, Abcam, UK), MMP-13
(1:2000, Abcam, UK), ADAMTS-4 (1:200, Abcam, UK), ADAMTS-5
(1:250, Abcam, UK) and GAPDH (1:2500, Abcam, UK) antibodies
overnight at 4C and horseradish peroxidase-conjugated secondary
antibodies were incubated for an hours at room temperature.
Immunoreactive bands were visualized by chemiluminescence
(Pierce ECL). The resulting auto-radiograms were then analyzed by
densitometry. Equal loading of proteins was qualiﬁed by detecting
GAPDH levels. Quantiﬁcationwas performedwith Image J software.
RNA transfection
The chondrocytes grown to 40% conﬂuence in a six-well plate
were transfected with FOXO3 siRNA (Cell signalling technology,
Danvers, MA, USA) using the Lipofectamine 2000 transfection re-
agent (Invitrogen) as our previous described21. All the experiments
were carried out 48 h after transfection. Knockdown of FOXO3 was
conﬁrmed by western blot analysis. The transfected cells were then
exposed to serum-deprivation medium for 24 h in the presence or
absence of Dex (106 M).
Flow cytometry
After being transfected with SiFOXO3 RNA, the chondrocytes
were treated with 106 M Dex in serum-free medium for 24 h. Then
the apoptosis incidence of the chondrocytes was detected by an
Annexin V-FITC apoptosis detection kit (BD Pharmingen, San Diego,
CA, USA). The samples were then tested by a ﬂuorescence-activated
cell sorter (Beckman Coulter, Miami, FL, USA). According to the user
manual, early apoptosis chondrocytes were deﬁned as Annexin V
positive and PI negative cells, and late apoptosis chondrocytes were
deﬁned as both Annexin V and PI positive cells.
Real-time PCR
The RNA of chondrocytes was isolated using a Trizol reagent
(Invitrogen, Carlsbad, CA, USA). According to the manufacturer's
instructions, 400 ng of total RNA was reverse-transcribed into
complementary DNA using the PrimeScript RT reagent kit (Takara
RR036A, Shiga, Japan). The expression of MMPs and aggrecanase
genes was tested by real-time PCR using SYBR Premix Ex Taq
(Takara, Shiga, Japan) and an ABI Prism 7500 sequence detection
system (Applied Bio-systems, Foster City, CA, USA). The thermalChondrocytes from FAI patients P value
3.01 ± 0.56 0.976
2.48 ± 0.48 0.802
plot andmean values obtained from each experiment. The real-time PCR results
etween the normal chondrocytes and FAI chondrocytes using independent t-test.
Table II
Primer of real-time PCR
Gene Primer Sequence (50 to 30)
MMP1 MMP1 F ACAACTGCCAAATGGGCTTGA
MMP1 R CTGTCCCTGAACAGCCCAGTACTTA
MMP13 MMP13 F CTGGGCCAGGGATTAATGGAG
MMP13 R CAATTTCATGAGCAGCAACGAGA
ADAMTS4 ADAMTS4 F ACTATCCCGGCTGCCCTTT
ADAMTS4 R TGAGTCTTAGCATGAGGCAGCAA
ADAMTS5 ADAMTS5 F AATGCACTTCAGCCACCATCA
ADAMTS5 R TCGTAGGTCTGTCCTGGGAGTTC
Collagen type I COL1A1 F ATGCCTGGTGAACGTGGT
COL1A1 R AGGAGAGCCATCAGCACCT
Collagen type II COL2A1 F CCCAGAGGTGACAAAGGAGA
COL2A1 R CACCTTGGTCTCCAGAAGGA
GAPDH GAPDH F ACCCAGAAGACTGTGGATGG
GAPDH R GAGGCAGGGATGATGTTCTG
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listed in Table II.
Statistical methods
The results of western blot analysis were repeatedly
measured for three times (conducted with samples from three
different donors). The other data were expressed as the mean of
multiple repeats ± S.D. of six independent experiments (indi-
vidual samples from every donor were studied in triplicate). Cells
from different donors were not pooled in any experiment. Sta-
tistical analyses were performed using the SPSS 20 statistical
software program (IBM, Armonk, NY, USA). The normality and
homogeneity of variance of data were tested before statistical
analysis. Statistically signiﬁcant differences between the groups
were determined by one-way repeated measures analysis of
variance (ANOVA) with Tukey's post test or Dunnett's test. TheFig. 1. Dex induced autophagy via increasing intracellular ROS. The chondrocytes were tre
presence of catalase for 24 h. (A) Dex increased intracellular ROS level in human chondrocyt
was inhibited by ROS scavenger, catalase. Autophagy ﬂux was expressed as the subtraction o
inhibitor from the amount of LC3-II in the presence of CQ for each of the conditions. (D) Rap
autophagy inhibitor, increased intracellular ROS level (n ¼ 6). (E) Dex up-regulated the expr
the ROS scavenger. Data are reported as scatter plots and mean values obtained from eachnonparametric test (Karuskal Wallis) was used when the condi-
tions for data properties were not fulfilled. The difference in the
mRNA expressions between FAI and normal chondrocytes was
measured by independent t-test. P-values<0.05 were considered
signiﬁcant.
Results
The induction of autophagy was in response to Dex-induced
increase of ROS
To investigate the effect of Dex on ROS, the intracellular ROS
levels were recorded after the treatment of different concentrations
Dex (106 M and 105 M) in serum deprivationmedium. The results
showed that Dex could signiﬁcantly up-regulate the endogenous
ROS level [Fig. 1(A)]. According to the guide of autophagy moni-
toring, the accurate measurement of autophagy activity is to detect
the autophagic ﬂux, which can be measured by the difference of
LC3-II protein levels in the absence and presence of lysosomal in-
hibitors26. To access the autophagic activity in the current study, we
investigated the autophagy ﬂux by detecting the accumulation of
LC3II (deﬁned as LC3 net ﬂux) using chloroquine to inhibit
lysosomes-mediated proteolysis. To determine the effect of Dex on
autophagy ﬂux, the chondrocytes were treated with of Dex
(106 M) in serum free medium in the presence and absence of
50 mM chloroquine (CQ, Sigma). To further detect the role of ROS on
Dex-induced autophagy, the chondrocytes were pre-treated with
catalase (sigma, 500 U/ml) for 3 h before the treatment of Dex at
37C. The results of western blot analysis showed that the treat-
ment of Dex increased the autophagy ﬂux [Fig. 1(B) and (C)].
Furthermore, using catalase, the ROS inhibitor, decreased Dex-
induced autophagy ﬂux [Fig. 1(B) and (C)]. All the results sug-
gested that Dex induced autophagy in human chondrocytes via a
ROS-dependent manner. Besides, Dex increased the expressions ofated with Dex (105 or 106 M) in serum deprivation medium in the absence or the
es (n ¼ 6). (B) and (C) Dex (106 M) increased autophagy ﬂux (n ¼ 3). This effect of Dex
f the amount of LC3-II (LC3 net ﬂux) in the absence of chloroquine (CQ), the autophagy
amycin, the autophagy inducer decreased intracellular ROS level. In contrast, 3-MA, the
essions of Bax, Bcl-2 as well as ULK1. These effects of Dex were suppressed by catalase,
experiment.
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medium. These effects of Dex were also suppressed by catalase
[Fig. 1(E)]. To further investigate the interaction between ROS and
autophagy, we measured the ROS level after the treatments of
autophagy inducer and inhibitor. The chondrocytes were pre-
treated with rapamycin (10 mM, SigmaeAldrich, St Louis, MO,
USA) or 3-MA (10 nM, SigmaeAldrich, St Louis, MO, USA) for 2 h
before the treatment of Dex. Rapamycin, the autophagy inducer,
signiﬁcantly decreased the intracellular level. In contrast, the ROS
level signiﬁcantly increased after the treatment of Dex when
autophagy was suppressed by 3-MA [Fig. 1(D)]. Taken together, the
results suggested that autophagy could protect the chondrocytes
from increasing levels of ROS. Dex induced autophagy via
increasing intracellular ROS level.Fig. 2. Dex increased the expressions of aggrecanases. The chondrocytes were cultured i
chondrocytes cultured in 10%FBS were used as control. (AeD) The results of real-time PCR a
mRNA expressions of MMP-1, MMP-13, ADAMTS-4 and ADAMTS-5. This side-effect of Dex w
western blotting analysis. This effect of Dex was also blocked by catalase. Data are reporteDex up-regulated catabolism of extra-cellular matrix in human
chondrocytes
To determine whether Dex could cause degenerative effects in
cartilage, we detected the mRNA expression of aggrecanases after
the treatment of Dex (106 M) for 24 h. To detect the role of ROS in
Dex-induced changes of matrix metabolism, the chondrocytes
were pre-treated with catalase (sigma, 500 U/ml) for 3 h before the
treatment of Dex at 37C. Both the mRNA and proteins expressions
of aggrecanases were signiﬁcantly up-regulated after the treatment
of Dex, suggesting that Dex could accelerate the catabolic process of
cartilage. Furthermore, this effect of Dex could be repressed by
catalase, indicating that Dex increased the expressions of aggre-
canases via a ROS signal pathway (Fig. 2).n the presence and absence of catalase in serum deprivation medium for 24 h. The
fter the treatment of Dex and catalase (n ¼ 6). The data showed that Dex increased the
as rescued by catalase. (E) Dex increased the expressions of MMPs and ADAMTSs using
d as scatter plots and mean values obtained from each experiment.
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pathway
To investigate the role of ROS/Akt signal in Dex-induced
expression of FOXO3, we measured the expression of p-Akt as
well as p-p70S6K after the treatment of Dex. The chondrocytes
were pre-treated with catalase (sigma, 500 U/ml) for 3 h before the
treatment of Dex at 37C. Dex treatment signiﬁcantly increased the
expression of p-Akt. Furthermore, this effect of Dex on the
expression of p-Akt was suppressed by catalase, suggested that Dex
increased p-Akt expression via up-regulation of intracellular ROS
level [Fig. 3(A) and (B)]. To further determine the role of Dex-AktFig. 3. Dex increased FOXO3 expression via ROS/Akt signal pathway The chondrocytes were
medium for 24 h (A) and (B) Dex up-regulated the activity of Akt signal pathway (n ¼ 3). Thi
Akt inhibitors, repressed Dex-induced up-regulation of FOXO3 and the expression of Bcl-2 (n
are reported as scatter plots and mean values obtained from each experiment.signal pathway in the regulation of FOXO3, we investigated the
expression of FOXO3 in the treatment of PI3K/Akt inhibitors, MK-
2206 (Selleck chemicals, USA) and LY294002 (Sigma, USA). The
chondrocytes were pre-treated with MK-2206 (1 mM) or LY294002
(10 mM) for 2 h before the treatment of Dex. The treatment of Dex
augmented the expression of p-Akt, Bcl-2, Bax as well as FOXO3
[Fig. 3(C) to (E)]. However, MK-2206 and LY294002, the PI3K/Akt
inhibitors, blocked the expression of FOXO3 in the treatment of
Dex, indicating that Dex increased FOXO3 expression through an
Akt dependent manner [Fig. 3(C) to (E)]. Taken together, all above
results suggested that Dex increased FOXO3 expression via ROS/Akt
signal pathway.cultured in the presence of ROS scavenger or PI3K/Akt inhibitors in serum deprivation
s effect of Dex was suppressed by catalase. (C) to (E) MK-2206 and LY294002, the PI3K/
¼ 3). Suppression of PI3K/Akt signal augmented Dex-induced expression of Bax. Data
Fig. 4. Dex induced autophagy via FOXO3 expression The chondrocytes were treated with 106 M Dex in serum deprivation medium for 24 h. (A) and (B) The chondrocytes were
transfected with FOXO3 siRNA (þ) or control siRNA (). Knockdown of FOXO3 expression was conﬁrmed by western blot analysis (n ¼ 3). (C) and (D) Silencing of FOXO3 resulted in
an increase of both early and late apoptosis incidences in human chondrocytes after the treatment of Dex (n ¼ 6). (E) and (F) Knockdown of FOXO3 associated with the suppression
of autophagy ﬂux, which was expressed as the subtraction of the amount of LC3-II (LC3 net ﬂux)in the absence of CQ from the amount of LC3-II in the presence of CQ for each of the
conditions. (n ¼ 3). (G) and (H) Silencing FOXO3 increased the intracellular ROS level and the expression of Bax as well as mTOR in the treatment of Dex. The expressions of ULK1
and Bcl-2 were suppressed by FOXO3 silencing. Data are reported as scatter plots and mean values obtained from each experiment.
C. Shen et al. / Osteoarthritis and Cartilage 23 (2015) 2279e22872284
C. Shen et al. / Osteoarthritis and Cartilage 23 (2015) 2279e2287 2285Dex induced autophagy through up-regulation of FOXO3 expression
To investigate the effect of FOXO3 on Dex-induced autophagy,
RNA interference technique was used for silencing the expression
of FOXO3 [Fig. 4(A) and (B)]. After the treatment of Dex for 24 h in
serum free medium, the western blot analysis results showed that
silencing of FOXO3 signiﬁcantly decreased the LC3 net ﬂux, sug-
gested that Dex increased autophagy activity via up-regulation of
FOXO3 [Fig. 4(E) and (F)]. Furthermore, silencing FOXO3 resulted in
an up-regulation of both early apoptosis and late apoptosis inci-
dence of chondrocytes, suggested that FOXO3 had a protective ef-
fect during the treatment of Dex [Fig. 4(C) and (D)]. Silencing of
FOXO3 also increased the intracellular level of ROS and expression
of Bax as well as mTOR [Fig. 4(G) and (H)]. The expressions of UKL1
and Bcl-2 were suppressed by FOXO3 silencing. All above results
suggested that Dex induced autophagy via ROS/Akt/FOXO3 signal
pathway.Discussion
Dex has been used in the management of OA and RA for de-
cades2,27,28. However, there has been a growth body of evidences
suggested that Dex might have serious side effects in collagen-
producing tissue. Therefore, there have been concerns about the
toxic effect of Dex on chondrocytes27,29,30. Recently, there was a
study demonstrated that autophagy, a catabolic process of energy
recycling, could protect chondrocytes from Dex-induced
apoptosis25. Nevertheless, the molecular mechanisms of Dex-
induced autophagy have been not fully elucidated. The work of
the current study showed that Dex could increase the intracellular
ROS level and consequently induce apoptosis in human chon-
drocytes. Administration of Dex also resulted in an increase in the
expression of MMPs and ADAMTSs via ROS-dependent manner.
These ﬁndings suggested that Dex could advance the degenerative
process of the cartilage via increasing intracellular ROS level.
Meanwhile, as a defense mechanism, autophagy was induced in
response to Dex-induced increase of ROS. Increased ROS level also
up-regulated the expressions of Akt and FOXO3. Silencing FOXO3
resulted in suppression of autophagy. Therefore, our ﬁnding sug-
gested that Dex induced autophagy through a ROS/Akt/FOXO3
signal pathway in human chondrocytes (see Fig. 5).
Chondrocytes survived in a hypoxia and avascular environ-
ment31. Therefore, anaerobic glycolysis is the key mechanism of
energy metabolism in chondrocytes. Despite ROS was an important
intracellular second messenger, excessive level of ROS might
disturb anaerobic metabolism of chondrocytes and disrupt the
homeostasis of the cartilage9,12,14. Actually, increasing level of ROSFig. 5. Dex induced autophagy via ROS/Akt/FOXO3 signal pathway. Dex increased the
intracellular level of ROS. ROS, in turns, activated Akt and FOXO3 and resulted in
increasing the autophagic ﬂux to protect the chondrocytes from Dex-induced increase
of ROS. Suppression of FOXO3 resulted in inhibition of autophagic activity and there-
fore increased the intracellular ROS level. Dex-induced up-regulation of ROS also
augmented the catabolic metabolism of extra-cellular matrix.has involved in the aging and degenerative process of the cartilages.
Several studies reported that ROS could increase the apoptosis
incidence and extracellular matrix degradation in chon-
drocytes8,15,32. Accumulation of intracellular ROS could damage the
mitochondria and cause oxidative stress. Recently, there were
studies reported that GC could dysregulate mitochondria and in-
crease oxidative stress in osteoblasts and chondrocytes6,8. Based on
these results, we tested that whether Dex had a toxic effect on
chondrocytes via increasing the ROS level. In the current study, our
results showed that GC could increase ROS and induce cell death in
human chondrocytes. Moreover, administration of Dex increased
the expressions of aggrecanases and apoptosis incidence in human
chondrocytes. These effects of Dex could be repressed by catalase, a
common ROS scavenger. Therefore, our results suggested that Dex
could accelerate the degenerative effect through increasing the
intracellular ROS level.
Autophagy had involved in the pathological process of OA
responsible to ROS/RNS (Reactive nitric species)21,23. Previously, our
results demonstrated that nitric oxide (NO), a common RNS, could
inhibit autophagy and decrease the cell viability in humanmeniscal
cells21. There has been evidence showed that ROS also interacted
with autophagy during the degenerative process of cartilage23,33.
Wu et al.33 found that OA chondrocytes had lower autophagic level
and higher level of ROS production compared with the normal
chondrocytes. Sasaki et al.23 found that induction of autophagy
could decrease the intracellular ROS level. In accordance with their
results, our study showed that autophagy was induced in response
to the Dex-induced up-regulation of ROS level in human chon-
drocytes. Increased level of ROS could cause oxidative stress and
induction of cell death in chondrocytes12. Several defense mecha-
nisms have been developed to protect cells against oxidative stress,
such as autophagy34. Induction of autophagy could decrease the
intracellular ROS level35. In contrast, inhibition of autophagy
resulted in an increase of both intracellular ROS and apoptosis rate
after the treatment of Dex. Taken together, our results showed that
the induction of autophagy protected chondrocytes from Dex-
induced apoptosis via decreasing ROS level.
As a common downstream gene of Akt, FOXO transcription
factors have involved in cell proliferation and survival in a variety of
tissues36,37. In human, FOXOs had bdegenerative processesciate
with aging and degenerative process of cartilage16e18,38. Akasaki
et al.16 reported the reduced expression of FOXO1 and FOXO3 in
human OA chondrocytes. Their results indicated that decreased
expression of FOXOs would increase the intracellular ROS level and
ROS-induced apoptosis17. In the current study, our data showed
that Dex increased intracellular ROS level, autophagy markers as
well as FOXO3 expression. Silencing FOXO3 resulted in reduction of
autophagy and cell viability of chondrocytes after the treatment of
Dex. Furthermore, silencing FOXO3 also increased the intracellular
ROS level. Actually, FOXO3 tightly associated with the regulation of
ROS scavenger genes, such as GPX-1 and SOD236. Therefore,
knockdown of FOXO3 also resulted in an increase of ROS level.
Taken together, our results showed that FOXO3 antagonist
increased ROS level by inducing autophagy.
In conclusion, our resulted showed Dex could up-regulate the
intracellular ROS level and degradation of matrix in human
chondrocytes. These ﬁndings suggested that long-term adminis-
tration of Dex could cause degenerative changes in cartilage. In-
duction of autophagy was a defense mechanism of chondrocytes
in response to Dex-induced increase of ROS. Furthermore, our
data showed that the silence of FOXO3 decreased autophagic ac-
tivity in chondrocytes, indicating that FOXO3 decreased ROS level
through up-regulation of autophagy. In summary, these ﬁndings
suggested that Dex induce autophagy via ROS-Akt-FOXO3 signal
pathway.
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